Progesterone signaling mediated through progesterone receptor membrane component-1 in ovarian cells with special emphasis on ovarian cancer

Steroids

Volumn 76, Issue 9, 2011, Pages 903-909

  Peluso, John J ^a  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

Ovarian Cancer; Ovary; PGRMC1; Progesterone

Indexed keywords

BINDING PROTEIN; CASPASE 14; CASPASE 2; CASPASE 3; CISPLATIN; GESTAGEN; INTERLEUKIN 1BETA CONVERTING ENZYME; MESSENGER RNA; ORAL CONTRACEPTIVE AGENT; PROGESTERONE; PROGESTERONE 4; PROGESTERONE RECEPTOR; PROGESTERONE RECEPTOR A; PROGESTERONE RECEPTOR B; PROGESTERONE RECEPTOR MEMBRANE COMPONENT 1; PROTEIN BAD; PROTEIN BCL 2; SMALL INTERFERING RNA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG;

ADVANCED CANCER; APOPTOSIS; CANCER INCIDENCE; CANCER RISK; CARCINOGENESIS; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; CYTOPLASM; EPITHELIUM CELL; GENE CONTROL; GENE EXPRESSION; GENE SILENCING; GENETIC TRANSCRIPTION; GRANULOSA CELL; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MITOSIS; NONHUMAN; ORAL CONTRACEPTION; OVARY CANCER; OVARY CELL CULTURE; OVARY TUMOR; PERITONEAL CAVITY; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; REGULATORY MECHANISM; REVIEW; TUMOR GROWTH; TUMOR VOLUME;

ANIMALS; CELL SURVIVAL; FEMALE; HUMANS; OVARIAN NEOPLASMS; PROGESTERONE; PROTEIN STRUCTURE, TERTIARY; RECEPTORS, PROGESTERONE; SIGNAL TRANSDUCTION; TRANSCRIPTION, GENETIC;

MUS; MUS MUSCULUS;

EID: 79959892278     PISSN: 0039128X     EISSN: 18785867     Source Type: Journal    
DOI: 10.1016/j.steroids.2011.02.011     Document Type: Review

References (31)

1. Salzberg M, Thurlimann B, Bonnefois H, Fink D, Rochlitz C, von Moos R, et al. Current concepts of treatment strategies in advanced or recurrent ovarian cancer. Oncology 2005;68:293-8. (Pubitemid 41160956)
2. Ho SM. Estrogen, progesterone and epithelial ovarian cancer. Reprod Biol Endocrinol 2003;1:73.
3. Fauvet R, Dufournet Etienne C, Poncelet C, Bringuier AF, Feldmann G, Darai E. Effects of progesterone and anti-progestin (mifepristone) treatment on proliferation and apoptosis of the human ovarian cancer cell line, OVCAR-3. Oncol Rep 2006;15:743-8.
4. Syed V, Mukherjee K, Godoy-Tundidor S, Ho SM. Progesterone induces apoptosis in TRAIL-resistant ovarian cancer cells by circumventing c-FLIPL overexpression. J Cell Biochem 2007;102:442-52. (Pubitemid 47519417)
5. Murdoch WJ, Van Kirk EA, Isaak DD, Shen Y. Progesterone facilitates cisplatin toxicity in epithelial ovarian cancer cells and xenografts. Gynecol Oncol 2008;110:251-5.
6. Chen X, Feng Y. Effect of progesterone combined with chemotherapy on epithelial ovarian cancer. Chin Med J (Engl) 2003;116:388-91. (Pubitemid 36432761)
7. Takahashi A, Kato K, Kuboyama A, Inoue T, Tanaka Y, Kuhara A, et al. Induction of senescence by progesterone receptor-B activation in response to cAMP in ovarian cancer cells. Gynecol Oncol 2009;113:270-6.
8. Davis M, Hitchcock A, Foulkes WD, Campbell IG. Refinement of two chromosome 11q regions of loss of heterozygosity in ovarian cancer. Cancer Res 1996;56:741-4. (Pubitemid 26055461)
9. Gabra H, Langdon SP, Watson JE, Hawkins RA, Cohen BB, Taylor L, et al. Loss of heterozygosity at 11q22 correlates with low progesterone receptor content in epithelial ovarian cancer. Clin Cancer Res 1995;1:945-53.
10. Hogdall EV, Christensen L, Hogdall CK, Blaakaer J, Gayther S, Jacobs IJ, et al. Prognostic value of estrogen receptor and progesterone receptor tumor expression in Danish ovarian cancer patients: from the 'MALOVA' ovarian cancer study. Oncol Rep 2007;18:1051-9.
11. Peluso JJ, Gawkowska A, Liu X, Shioda T, Pru JK. Progesterone receptor membrane component-1 regulates the development and cisplatin sensitivity of human ovarian tumors in athymic nude mice. Endocrinology 2009;150:4846-54.
12. Romero-Sanchez M, Peiper SC, Evans B, Wang Z, Catasus L, Ribe A, et al. Expression profile of heptahelical putative membrane progesterone receptors in epithelial ovarian tumors. Hum Pathol 2008;39:1026-33.
13. Peluso JJ. Multiplicity of progesterone's actions and receptors in the mammalian ovary. Biol Reprod 2006;75:2-8. (Pubitemid 43946334)
14. Falkenstein E, Eisen C, Schmieding K, Krautkramer M, Stein C, Losel R, et al. Chemical modification and structural analysis of the progesterone membrane binding protein from porcine liver membranes. Mol Cell Biochem 2001;218:71-9. (Pubitemid 32294137)
15. Cahill MA. Progesterone receptor membrane component 1: an integrative review. J Steroid Biochem Mol Biol 2007;105:16-36. (Pubitemid 47211947)
16. Peluso JJ, Romak J, Liu X. Progesterone receptor membrane component-1 (PGRMC1) is the mediator of progesterone's antiapoptotic action in spontaneously immortalized granulosa cells as revealed by PGRMC1 small interfering ribonucleic acid treatment and functional analysis of PGRMC1 mutations. Endocrinology 2008;149:534-43. (Pubitemid 351159360)
17. Peluso JJ, Liu X, Gawkowska A, Johnston-MacAnanny E. Progesterone activates a progesterone receptor membrane component 1-dependent mechanism that promotes human granulosa/luteal cell survival but not progesterone secretion. J Clin Endocrinol Metab 2009;94:2644-9.
18. O'Brien ME, Dowsett M, Fryatt I, Wiltshaw E. Steroid hormone profile in postmenopausal women with ovarian cancer. Eur J Cancer A 1994;30:442-5. (Pubitemid 24171946)
19. Halperin R, Hadas E, Langer R, Bukovsky I, Schneider D. Peritoneal fluid gonadotropins and ovarian hormones in patients with ovarian cancer. Int J Gynecol Cancer 1999;9:502-7. (Pubitemid 30027556)
20. Peluso JJ, Liu X, Saunders MM, Claffey KP, Phoenix K. Regulation of ovarian cancer cell viability and sensitivity to cisplatin by progesterone receptor membrane component-1. J Clin Endocrinol Metab 2008;93:1592-9. (Pubitemid 351656493)
21. Kenny HA, Kaur S, Coussens LM, Lengyel E. The initial steps of ovarian cancer cell metastasis are mediated by MMP-2 cleavage of vitronectin and fibronectin. J Clin Invest 2008;118:1367-79. (Pubitemid 351500430)
22. McDonnel AC, Van Kirk EA, Isaak DD, Murdoch WJ. Effects of progesterone on ovarian tumorigenesis in xenografted mice. Cancer Lett 2005;221:49-53. (Pubitemid 40387907)
23. Spannuth WA, Sood AK, Coleman RL. Angiogenesis as a strategic target for ovarian cancer therapy. Nat Clin Pract Oncol 2008;5:194-204. (Pubitemid 351493679)
24. Peluso JJ. Non-genomic actions of progesterone in the normal and neoplastic mammalian ovary. Semin Reprod Med 2007;25:198-207. (Pubitemid 46676906)
25. Peluso JJ, Liu X, Gawkowska A, Lodde V, Wu CA. Progesterone inhibits apoptosis in part by PGRMC1-regulated gene expression. Mol Cell Endocrinol 2010;320:153-61.
26. Rasooly R, Schuster GU, Gregg JP, Xiao JH, Chandraratna RA, Stephensen CB. Retinoid x receptor agonists increase bcl2a1 expression and decrease apoptosis of naive T lymphocytes. J Immunol 2005;175:7916-29. (Pubitemid 41798352)
27. Yin W, Raffelsberger W, Gronemeyer H. Retinoic acid determines life span of leukemic cells by inducing antagonistic apoptosis-regulatory programs. Int J Biochem Cell Biol 2005;37:1696-708. (Pubitemid 40719648)
28. Kaipia A, Hsu SY, Hsueh AJ. Expression and function of a proapoptotic Bcl-2 family member Bcl-XL/Bcl-2-associated death promoter (BAD) in rat ovary. Endocrinology 1997;138:5497-504. (Pubitemid 27509714)
29. Verma UN, Surabhi RM, Schmaltieg A, Becerra C, Gaynor RB. Small interfering RNAs directed against beta-catenin inhibit the in vitro and in vivo growth of colon cancer cells. Clin Cancer Res 2003;9:1291-300. (Pubitemid 36418379)
30. Yallapu MM, Jaggi M, Chauhan SC. Scope of nanotechnology in ovarian cancer therapeutics. J Ovarian Res 2010;3:19.
31. Peluso JJ, Pappalardo A, Losel R, Wehling M. Progesterone membrane receptor component 1 expression in the immature rat ovary and its role in mediating progesterone's antiapoptotic action. Endocrinology 2006;147:3133-40. (Pubitemid 43764649)